CRMD - CorMedix GAAP EPS of -$0.25 misses by $0.01

2023-08-08 07:33:48 ET

• CorMedix press release ( NASDAQ: CRMD ): Q2 GAAP EPS of -$0.25 misses by $0.01 .
• Joe Todisco, CorMedix CEO, commented, “we are pleased with the progress that we have made toward our goal of achieving a potential FDA approval of DefenCath later this year. With the recent financing completed, we believe CorMedix is in a strong financial position and we are heavily focused on operational execution and commercial preparedness ahead of our target action date in November. We look forward to providing updates as we aim to deliver on our commitment to reducing the risk of infections in patients receiving hemodialysis via central venous catheters.”

For further details see: